A Novel Treg Augmenting Therapy for Patients with Alopecia Areata

Year: 
2019 to 2021
Investigator-Initiated Research Grant Opportunities
Michael D. Rosenblum, MD , Principal Investigator
University of California San Francisco

Significance

If successful, this study may help pave the way for future clinical trials testing the safety and efficacy of regulatory T cell (Treg) augmenting therapies in patients with alopecia areata.

Purpose

This project will examine the function of regulatory T cells (Tregs) in the activation and differentiation of hair follicle stem cells in alopecia areata and determine whether the activity of Tregs can be modulated in alopecia areata using a novel IL-2 molecule.